AIMS: Cysteamine, the only drug available for the treatment of cystinosis in paediatric patients, is available as the hydrochloride, the bitartrate and as sodium phosphocysteamine salts. It has been suggested that cysteamine bitartrate and phosphocysteamine are better tolerated and may have a better bioavailability than cysteamine hydrochloride. This has, however, never been demonstrated. METHODS: We compared the pharmacokinetics and tolerance of these three formulations of cysteamine in 18 healthy adult male volunteers in a double-blind, latin-square, three-period, single oral dose cross-over relative bioavailability study. RESULTS: No statistical difference was found between relative bioavailabilities, AUC (0, infinity) (geometric mean and s.d. in micromol l(-1) h: 169+/-51, 158+/-46, 173+/-49 with cysteamine hydrochloride, phosphocysteamine and cysteamine bitartrate respectively), Cmax (geometric mean and s.d. in micromol l(-1); 66+/-25.5, 59+/-12, 63+/-20) and tmax (median and range in h: 0.88 (0.25-2), 1.25 (0.25-2), 0.88 (0.25-2)) with each of the three forms of cysteamine tested. Bioequivalence statistics (90% confidence intervals) showed non equivalence of Cmax of cysteamine base as the only non equivalence of pharmacokinetics between the three formulations: 90% CI for Cmax relative ratios to cysteamine hydrochloride were [75.6-105.81 for phosphocysteamine and [74.2-124.2] for cysteamine bitartrate. The only significant adverse event was vomiting whose frequency was inversely correlated with body weight (Spearman's r=-0.76, P<0.001). The nature of the salt tested did not influence vomiting. CONCLUSIONS: While none of the three forms of cysteamine tested has a clear advantage over the others in terms of pharmacokinetics and tolerance profile, this should now however be addressed in patients treated for cystinosis during repeat administrations.
RCT Entities:
AIMS: Cysteamine, the only drug available for the treatment of cystinosis in paediatric patients, is available as the hydrochloride, the bitartrate and as sodium phosphocysteamine salts. It has been suggested that cysteamine bitartrate and phosphocysteamine are better tolerated and may have a better bioavailability than cysteamine hydrochloride. This has, however, never been demonstrated. METHODS: We compared the pharmacokinetics and tolerance of these three formulations of cysteamine in 18 healthy adult male volunteers in a double-blind, latin-square, three-period, single oral dose cross-over relative bioavailability study. RESULTS: No statistical difference was found between relative bioavailabilities, AUC (0, infinity) (geometric mean and s.d. in micromol l(-1) h: 169+/-51, 158+/-46, 173+/-49 with cysteamine hydrochloride, phosphocysteamine and cysteamine bitartrate respectively), Cmax (geometric mean and s.d. in micromol l(-1); 66+/-25.5, 59+/-12, 63+/-20) and tmax (median and range in h: 0.88 (0.25-2), 1.25 (0.25-2), 0.88 (0.25-2)) with each of the three forms of cysteamine tested. Bioequivalence statistics (90% confidence intervals) showed non equivalence of Cmax of cysteamine base as the only non equivalence of pharmacokinetics between the three formulations: 90% CI for Cmax relative ratios to cysteamine hydrochloride were [75.6-105.81 for phosphocysteamine and [74.2-124.2] for cysteamine bitartrate. The only significant adverse event was vomiting whose frequency was inversely correlated with body weight (Spearman's r=-0.76, P<0.001). The nature of the salt tested did not influence vomiting. CONCLUSIONS: While none of the three forms of cysteamine tested has a clear advantage over the others in terms of pharmacokinetics and tolerance profile, this should now however be addressed in patients treated for cystinosis during repeat administrations.
Authors: W A Gahl; G F Reed; J G Thoene; J D Schulman; W B Rizzo; A J Jonas; D W Denman; J J Schlesselman; B J Corden; J A Schneider Journal: N Engl J Med Date: 1987-04-16 Impact factor: 91.245
Authors: J A Schneider; K F Clark; A A Greene; J S Reisch; T C Markello; W A Gahl; J G Thoene; P K Noonan; K A Berry Journal: J Inherit Metab Dis Date: 1995 Impact factor: 4.982
Authors: Daryl M Okamura; Nadia M Bahrami; Shuyu Ren; Katie Pasichnyk; Juliana M Williams; Jon A Gangoiti; Jesus M Lopez-Guisa; Ikuyo Yamaguchi; Bruce A Barshop; Jeremy S Duffield; Allison A Eddy Journal: J Am Soc Nephrol Date: 2013-09-05 Impact factor: 10.121
Authors: Maria Borrell-Pagès; Josep M Canals; Fabrice P Cordelières; J Alex Parker; José R Pineda; Ghislaine Grange; Elzbieta A Bryson; Martine Guillermier; Etienne Hirsch; Philippe Hantraye; Michael E Cheetham; Christian Néri; Jordi Alberch; Emmanuel Brouillet; Frédéric Saudou; Sandrine Humbert Journal: J Clin Invest Date: 2006-04-06 Impact factor: 14.808
Authors: Eric B Belldina; Mei Y Huang; Jerry A Schneider; Richard C Brundage; Timothy S Tracy Journal: Br J Clin Pharmacol Date: 2003-11 Impact factor: 4.335